Yes, true. I think a good percent of phase II, but I am sure others do not play out in early stages.
Mostly I was interested in the broad anti-TNF, anti-alpha, downstream signaling, immunomodulator, Cytokin, and Interleukin classes. I thought there was only two classes. Each new class is also an advance in understainding of causal mechanisms, and I hope that these understandings and advances in gut microbe research come together relatively quickly over the next decade.
Plus, like Stelera, some in RA pipeline will cross over to CD and UC. IF bio-similars can help control costs, and if genetic testing can pinpoint most likely drugs to work for each person, then I don't worry so much about
aging with UC.
Post Edited (DBwithUC) : 1/10/2017 9:03:33 AM (GMT-7)